Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Divarasib vs Immunotherapy or Observation in Resected Stage II-III KRAS G12C-Positive NSCLC
NCT07541170Phase 3Recruiting
- Sponsor
- Roche
- Start
- Oct 2026
- Primary completion
- Jan 2032
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Divarasib with Control: Pembrolizumab or Nivolumab or Observation (2 arms). Primary endpoint: Disease-free Survival at 5 years. Started Oct 2026; status: recruiting.
02
Drugs
divarasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07541170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07541170.